Metabolite perturbations in type 1 diabetes associated with metabolic dysfunction-associated steatotic liver disease

作者：Adeyinka Taiwo, Ronald A. Merrill, Linder Wendt, Daniel J. Pape, Himani Thakkar, J. Alan Maschek, James E. Cox, Scott A. Summers, Bhagirath Chaurasia, Nikitha Pothireddy, B. M. Carlson, Antonio Sánchez, Patrick Ten Eyck, Diana Jalal, Ayotunde O. Dokun, Eric B. Taylor, William I. Sivitz · 发表于：Frontiers in Endocrinology · 年份：2025 · DOI：10.3389/fendo.2025.1500242 · 被引用次数：5 · 研究领域：Liver Disease Diagnosis and Treatment、Metabolomics and Mass Spectrometry Studies、Diabetes and associated disorders

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Although MASLD has been widely studied in persons with Type 2 diabetes (T2D), far less in known about the pathogenesis and severity of MASLD in Type 1 diabetes (T1D). Objectives: Determine metabolic perturbations associated with MASLD in persons with T1D. Study Design: We conducted a cross-sectional study of 30 participants with T1D. Based on the results of a FibroScan, participants were stratified as cases (MASLD) or controls. Metabolomic analyses were performed on plasma obtained from all participants after an overnight (after midnight) fast. Results: 17 of 30 participants were classified as cases (MASLD) and 13 as controls. Cases had higher BMI (p=<0.001) and were taking higher daily insulin doses than controls (p=0.003). Metabolomic analyses revealed that those with MASLD had elevated levels of gluconeogenic substrates pyruvate (p=0.001) and lactate (p=0.043), gluconeogenic amino acids alanine (p<0.001) and glutamate (p=0.004), phenylalanine (p=0.003), and anthranilic acid (p=0.015). Lipidomics revealed, elevated ceramides (P=0.02), diacylglycerols (p=0.0009) and triacylglycerols (P=0.0004) in MASLD group. In those with MASLD, the acylcarnitines, isovalerylcarnitine (CAR.5.0) (P=0.002) and L-Palmitoylcarnitine (CAR.16.0) (P=0.048), were elevated. Pathway analyses using MetaboAnalyst ...